Drug Profile
Research programme: hepatitis C virus therapies - Presidio Pharmaceuticals/Numerate
Latest Information Update: 29 Apr 2010
Price :
$50
*
At a glance
- Originator Numerate; Presidio Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 24 Apr 2010 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 20 Feb 2008 Preclinical trials in Hepatitis C in USA (unspecified route)